Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Gain access to all of the market research and financial analytics used in the preparation of this article plus exclusive content and pharma, healthcare and biotech investment recommendations and research / analytics by subscribing to my channel, Haggerston BioHealth.I have been considering Ionis (NASDAQ: IONS ) as a potential "strong buy" opportunity for some time. I covered the Carlsbad, California-based developer of antisense, oligonucleotide therapeutics on multiple occasions, most recently in May, short ...